Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Table 1 Patient characteristics of the clinical trials

Study	N	Male	Female	Age (Years)	Histology of Lung cancer						Quality of Life	End point
Study	N	Male	Female	Age (Years)	LAC	LSCC	SCLC	LCLC	ADSC	Other	Quality of Life	End point
Yuquan L 2005 [25]	36	25	11	–	29		7	0	0	0	KPS ≥ 50	ORR, DCR, AEs
Do W 2005 [20]	62	–	–	24–81	–	–	–	–	–	–	KPS ≥ 50	ORR, DCR, AEs
Yanhao W 2006 [13]	56	37	19	24–80	40	5	6	0	3	2	KPS ≥ 50	ORR, DCR, AEs
Zhijun W 2007 [26]	84	61	23	36–73	56	16	0	0	12	0	ECOG≤2	ORR, DCR, AEs
Shimeng F 2010 [22]	73	43	30	38–76	51	11	11	0	0	0	KPS ≥ 60	ORR, DCR, AEs
Hua Z 2010 [9]	58	31	27	39–81	47	10	0	0	1	0	KPS ≥ 60	ORR, DCR, AEs
Xiqiang W 2010 [24]	54	–	–	36–72	32	19	0	3	0	0	ECOG≤2	ORR, DCR, AEs
Haiyan C 2015 [10]	53	25	28	40–81	36	13	−0	0	0	4	KPS ≥ 60	ORR, DCR, AEs
Jin L 2015 [12]	55	–	–	62.5	55	0	0	0	0	0	KPS ≥ 60	ORR, DCR, SI, AEs
Tao H 2016 [23]	60	38	22	41–78	60						–	ORR, DCR, AEs
Chun W 2016 [19]	64	35	29	65–89	37	27	0	0	0	0	–	ORR, DCR, AEs
Hua Z 2017 [21]	39	19	20	61–88	32	7	0	0	0	0	KPS ≥ 50	ORR, DCR, AEs

N number of patients, M/F male/ female, LAC lung adenocarcinoma, LSCC lung squamous cell carcinoma, SCLC small cell lung cancer, LCLC large cell lung cancer, ADSC adenosquamous carcinoma, KPS Karnofsky performance scale index, ECOG performance scale index made by Eastern Cooperative Oncology Group, ORR objective response rate, DCR disease control rate, SI symptom improvement, AEs adverse effects

ISSN: 1471-2466